New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2013
16:32 EDTTXT, EOPN, ALKS, ACUR, CRUS, ENDP, AAPL, BACOn The Fly: Closing Wrap
Stocks on Wall Street were sharply lower as the S&P and Nasdaq gave back all of yesterday's gains. The Dow returned almost all of yesterday's advance, logging its third consecutive triple-digit move. ECONOMIC EVENTS: The Federal Reserve's Beige Book, released this afternoon, said that economic activity expanded at a moderate pace, which was in-line with expectations. In Europe, Germany's top central banker said it may take Europe a decade to recover from its debt crisis and ratings agency Egan Jones reportedly cut its rating on Germany to A from A+. COMPANY NEWS: Apple's (AAPL) shares fell below $400 during the session and closed down $23.44, or 5.5%, at $402.80. One of the company's suppliers, Cirrus Logic (CRUS), estimated that revenue for its current quarter would be significantly below expectations, reinforcing expectations from some analysts that second quarter iPhone shipments will be much lower than in the first quarter. Cirrus shares lost $3.36, or 15.69%, to $18.05 following its warning and a number of other suppliers with exposure to Apple's supply chain fell also... Bank of America (BAC) reported headline earnings that missed consensus, though its revenue topped expectations. The bank also announced it has agreed to a $500M settlement in principle that would dismiss more suits brought against its Countrywide unit related to residential mortgage-backed securities. BofA was the Dow's worst performer following its quarterly report, falling 58c, or 4.72%, to $11.70. MAJOR MOVERS: Among notable gainers were shares of Acura Pharma (ACUR), up 73c, or 33.95%, to $2.88, and Endo Health (ENDP), up $1.10, or 3.16%, to $35.96 after the FDA announced it will not approve generic versions of non-tamper-resistant OxyContin. Also higher was Alkermes (ALKS), up $4.12, or 16.09%, to $29.72 after reporting preliminary results from a study of a drug candidate for major depressive disorder. Among the noteworthy losers was E2open (EOPN), down $4.49, or 24.18%, to $14.08 after its earnings and guidance fell well short of expectations. Also lower were shares of Textron (TXT), down $3.94, or 13.42%, to $25.41 after the company reported first quarter results that missed expectations and it cut its full-year view... INDICES: The Dow was down 138.19, or 0.94%, to 14,618.59; the Nasdaq was down 59.96, or 1.84%, to 3,204.67; and the S&P 500 was down 22.56, or 1.43%, to 1,552.01.
News For AAPL;CRUS;BAC;ENDP;ACUR;ALKS;EOPN;TXT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 >>
August 23, 2015
19:03 EDTAAPLApple hires Tesla engineer for 'special projects' division
Subscribe for More Information
14:23 EDTAAPLApple, Micron shares look like bargains, Barron's says
Subscribe for More Information
August 21, 2015
16:01 EDTBAC, AAPLOptions Update; August 21, 2015
Subscribe for More Information
16:01 EDTALKSAlkermes provides update on FDA review of ARISTADA
Alkermes announced that the U.S. FDA has advised Alkermes that it will not be able to complete its review of the New Drug Application for ARISTADA for the treatment of schizophrenia by the Prescription Drug User Fee Act action date of Aug. 22, 2015. The FDA indicated that this delay was expected to be brief, measured in terms of weeks, but could not confirm specific timing. The FDA also indicated that no additional data or information is required from Alkermes at this time. "We are confident in the ARISTADA program and our NDA submission, and we will work closely with the FDA as they complete their review," said Elliot Ehrich, M.D., Chief Medical Officer of Alkermes. "We look forward to bringing ARISTADA to market as a potential new treatment option to help address the significant unmet medical needs of patients living with schizophrenia."
13:50 EDTAAPLOn The Fly: Weekly technical notes, Gold, S&P 500, Germany, China, Energy
Subscribe for More Information
12:49 EDTAAPLReport: Apple may be working on smart bands for Watch, Apple Insider says
Apple may be working on "smart bands" for the Apple Watch product in order to add more health tracking functions, reports Apple Insider, citing Czech website Letem Svetem Applem. Citing unnamed sources, the Czech website said Apple is planning to announce new bands that will connect the hidden port of the Apple Watch and add functionality to the device. The smart bands could launch as early as 2016. Reference Link
12:43 EDTAAPLJim Chanos says still long Apple, short HP
Subscribe for More Information
10:23 EDTAAPLApple falls, levels to watch
Subscribe for More Information
09:34 EDTAAPL, BACActive equity options trading on open
Active equity options trading on open: AAPL FB BAC NFLX DIS TSLA TWTR
08:40 EDTBACCanadian Security Traders Association to hold a conference
Subscribe for More Information
08:11 EDTAAPLDaimler AG could collaborate with Google, Apple, Reuters says
Subscribe for More Information
06:01 EDTAAPLABI Research: Portable PC sales to remain flat in 2015, DigiTimes says
Subscribe for More Information
August 20, 2015
16:00 EDTBAC, AAPLOptions Update; August 20, 2015
iPath S&P 500 VIX Short-Term Futures up 1.49 to 17.70. Option volume leaders: AAPL BAC FB NFLX DIS INTC BABA MU
12:24 EDTAAPLVIX methodology for Apple up 12% to 33.29
10:22 EDTAAPLApple falls, levels to watch
Subscribe for More Information
09:36 EDTAAPL, BACActive equity options trading on open
Subscribe for More Information
08:45 EDTAAPLApple iPhone 6S may not pressure gross margins, says Bernstein
Subscribe for More Information
06:13 EDTAAPLApple's Australian bonds raise $1.2B within two hours, SMH reports
Subscribe for More Information
06:07 EDTAAPLApple's 12.9-inch iPad to feature displays from Sharp, DigiTimes reports
Subscribe for More Information
05:55 EDTCRUSCirrus Logic pullback a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Ruben Roy recommends using the recent pullback in shares of Cirrus Logic as a buying opportunity. The stock is down 23% from the post earnings highs in late July, Roy tells investors in a research note. After hosting investor meetings with Cirrus Logic CEO Jason Rhode, Roy believes increasing dollar content in upcoming handsets and revenue diversification will remain key themes for the company over the next 18 months. He views Cirrus as the "strongest beneficiary" from expanding voice activation applications in portable and mobile devices. Roy reiterates an Overweight rating on the stock with a $44 price target.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use